Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Study of Sildenafil Citrate in Pediatric Pulmonary Arterial Hypertension
2016-003978-41Phase 3
- Sponsor
- Pfizer
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sildenafil in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Primary endpoints: Change from baseline in pulmonary vascular resistance index (PVRI) at week 16, Change in WHO functional class at week 16 and 1 more.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2016-003978-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003978-41.